Foralumab | Jotup

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

Retrieved on:

Donnerstag, Mai 30, 2024

Patient, CMSC, Organization, Mass, Mass General Brigham, Tiziana, Foralumab, FDA, DSM-IV codes, Multiple sclerosis, Cone Health Women's Hospital, Research, Neurology, Fatigue, Multiple sclerosis research, Hospital, MFIS, Pharmaceutical industry

The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.

Key Points:

The award ceremony will take place on May 30, 2024 at the Consortium of Multiple Sclerosis Centers annual meeting being held in Nashville, Tennessee.
“We are thrilled to see Dr. Howard Weiner recognized with the ‘Giants of MS’ award for his exceptional achievements in MS research,” said Gabriele Cerrone, Chairman, acting CEO, and founder of Tiziana Life Sciences.
Weiner's relentless pursuit of scientific excellence and commitment to improving patient outcomes also exemplifies the values we uphold at Tiziana.
This award acknowledges individuals who have demonstrated extraordinary leadership and innovation in the field of MS research.

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Retrieved on:

Freitag, April 19, 2024

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a study related to its lead candidate, foralumab, was highlighted in Neurology Today®, the official news source of the American Academy of Neurology (AAN), in an article titled, “Anti-CD3 Antibody Foralumab Shows Promise in PIRA, Measured by Novel PET Ligand.”

Key Points:

A systemic review published in JAMA Neurology[1] in October 2023 found that PIRA is the most frequent manifestation of disability accumulation across the full spectrum of traditional multiple sclerosis (MS) phenotypes.
“PIRA is a condition that poses a major unmet need for patients with multiple sclerosis,” stated Dr. Singhal.
“Currently, there are no disease-modifying therapies approved for this category of progressive MS patients.
The study is designed to be open-label and is based on data from the Expanded-Access Program evaluating foralumab in na-SPMS patients that is currently underway.

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Retrieved on:

Freitag, Januar 5, 2024

Effectiveness of GLP-1ra non T2D obesity was recently shown in the >17,600 patient SELECT trial by Novo Nordisk (N Engl J Med 2023; 389:2221-2232(NCT03574597).

Key Points:

Effectiveness of GLP-1ra non T2D obesity was recently shown in the >17,600 patient SELECT trial by Novo Nordisk (N Engl J Med 2023; 389:2221-2232(NCT03574597).
SELECT showed a 20% reduction of major adverse cardiovascular events (MACE) such as heart attack, stroke, and peripheral vascular disease, with semaglutide.
The risk of adverse cardiovascular events could be reduced further by the combination of intranasal foralumab and a GLP-1ra.
The patent application describes the potential for foralumab to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease.

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Retrieved on:

Mittwoch, Oktober 18, 2023

Mass General Brigham, FDA, Harvard Medical School, Food, Neurology, HMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Multiple sclerosis, Mass, Sclerosis, Patient, Hospital, MS, Pharmaceutical industry, Brigham, Foralumab

NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis.

Key Points:

NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis.
The U.S. Food and Drug Administration (FDA) has allowed multiple sclerosis patients to take home and self-administer Intranasal Foralumab, a groundbreaking treatment developed by Tiziana Life Sciences.
Intranasal Foralumab, a novel biologic therapy, has demonstrated remarkable potential in the management of multiple sclerosis.
This step significantly aligns with our mission to make innovative therapies more accessible to patients and ultimately improve their quality of life.

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Retrieved on:

Mittwoch, Oktober 11, 2023

Foralumab, Congress, Multiple sclerosis, Research, Treatment, Disability, Safety, Vaccine, Pharmaceutical industry

Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes”

Key Points:

Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes”
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a late breaking poster titled, “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes”, will be presented at the 39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) being held in Milan, Italy, October 11-13, 2023.

Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease

Retrieved on:

Donnerstag, August 17, 2023

Interview, Phase II, Food and Drug Administration, Coronavirus Scientific Advisory Board, Inflammation, Foralumab, Investigational New Drug, Mass, DSM-IV codes, Hospital, FDA, IND, Neurology, Alzheimer's disease, Food, Neuroinflammation, Pharmaceutical industry, Brigham, Bloomberg

Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.

Key Points:

Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.
Dr. Weiner is the Chairman of Tiziana's Scientific Advisory Board and his deep expertise and experience places him in a unique position to provide valuable insights into the potential impact of Tiziana's technology.
“Alzheimer's disease, a difficult-to-treat neurodegenerative disorder affecting millions worldwide, represents a significant unmet need and has long been a challenge in medical research,” stated Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences.
“Tiziana's commitment to innovation has driven us to explore novel solutions to this complex condition via intranasal foralumab, that, in previous studies, has been shown to modulate and dampen neuroinflammation.

Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease

Retrieved on:

Dienstag, August 15, 2023

Flexner Report, Pathology, Brain, Harvard Medical School, Foralumab, Alzheimer's disease, Investigational New Drug, Patient, Mass, Neurology, DSM-IV codes, Hospital, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Disease, Pharmaceutical industry, Brigham

Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.

Key Points:

Foralumab could be a potentially groundbreaking treatment for Alzheimer’s disease, given it targets the disease’s underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.
Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, stated, "The IND clearance is a significant milestone for Tiziana that highlights the strength and the therapeutic potential of foralumab.
We are deeply committed to advancing the field of neurodegenerative diseases and bringing much-needed relief to patients suffering from Alzheimer's with a novel therapeutic approach.
Foralumab shows great promise in targeting the pathological hallmarks of the disease, and I am optimistic about its potential to offer a breakthrough treatment option for patients suffering from this devastating condition.

Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

Retrieved on:

Donnerstag, Mai 25, 2023

KOL, CD3, Neurodegenerative disease, Inflammation, Foralumab, Mass, DSM-IV codes, Microglia, Hospital, SPMS, Pharmaceutical industry, Vaccine, Brigham

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event to discuss the potential of foralumab in non-active secondary progressive multiple sclerosis (na SPMS) on Monday, June 5, 2023 at 12:30 PM ET.

Key Points:

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event to discuss the potential of foralumab in non-active secondary progressive multiple sclerosis (na SPMS) on Monday, June 5, 2023 at 12:30 PM ET.
The event will feature Howard Weiner, M.D.
The webinar will focus on foralumab, an intranasal fully human monoclonal antibody targeting the CD3 receptor, and its potential for reducing inflammation by modulating the microglia.
Foralumab has a novel mechanism of action that increases production of naïve-like T cells and Tregs, while simultaneously decreasing the production of effector T cells.

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

Retrieved on:

Montag, April 10, 2023

University, Fondazione Prada, Foralumab, Episcopal conference, Poster, Conference, Pharmaceutical industry, Exhibition

Exhibition will run from March 31st to May 21st, 2023, at Prada Rong Zhai

Key Points:

Exhibition will run from March 31st to May 21st, 2023, at Prada Rong Zhai
Scientific Conference will be held on April 20th, 2023, at Prada Rong Zhai
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that poster presentations on intranasal foralumab are being presented at the “Preserving the Brain” scientific conference and exhibit held at the Fondazione Prada in Rong Zhai in Shanghai.
“Preserving the Brain” is a scientific forum and exhibit on neurodegenerative diseases as part of the “Human Brains” neuroscience project held in Fondazione Prada in Shanghai, China.
“I am absolutely thrilled that foralumab has once again been invited to be presented at the Fondazione Prada’s “Preserving the Brain” international forum, this year being held in Shanghai,” commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana Life Sciences.
“Having our lead asset Foralumab, the only fully human anti-CD3 highlighted again at an esteemed cultural institution such as Fondazione Prada only further validates our passion and focus to advance this novel therapy in neuroinflammatory diseases.”

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

Retrieved on:

Dienstag, März 28, 2023

Mab, Clinical trial, Foralumab, SPMS, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Food, Pharmacist, Pharmaceutical industry

Tiziana plans to accept the FDA’s recommendations and intends to start a Phase 2 study in the third quarter of 2023 as previously announced.

Key Points:

Tiziana plans to accept the FDA’s recommendations and intends to start a Phase 2 study in the third quarter of 2023 as previously announced.
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb).
“Tiziana has reached an important regulatory milestone as it proceeds with the first ever intranasal foralumab clinical trial,” commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer.
“This upcoming quarter, we will update the Phase 2 protocol with the FDA’s suggestions and plan to start the Phase 2 clinical trial by holding our first investigator’s meeting in Q3 2023.”